FDA Recalls Tadalafil Tablets Due to Manufacturing Practice Deviations
Accord Healthcare's Tadalafil 5 mg tablets are being recalled due to deviations from current good manufacturing practices identified during an FDA inspection. Approximately 1,113,264 bottles were distributed across the United States, Puerto Rico, and Canada.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. The recall results from current good manufacturing practice deviations identified during inspection. Per the rubric, this qualifies as a risk-of-harm product where injury has not yet been reported, warranting a High severity score.
Plain-English summary
Accord Healthcare, Inc. is recalling Tadalafil 5 mg tablets due to current good manufacturing practice (CGMP) deviations identified during an FDA inspection. Approximately 1,113,264 bottles with multiple lot codes and expiration dates ranging from April 2023 to August 2025 are affected.
The recall was initiated following an FDA inspection that identified deviations from manufacturing standards. These deviations relate to how the product was manufactured and quality-controlled, though the specific nature of the manufacturing issues was not disclosed in the recall notice.
The affected products were distributed to pharmacies and healthcare facilities throughout the United States, including Puerto Rico, and Canada. Consumers and healthcare providers who have this medication should check their supply against the provided lot numbers and expiration dates. Patients should not discontinue their medication without consulting a healthcare provider; instead, they should contact their pharmacy to determine if they have affected product and obtain a replacement if needed.
The recalled product
- Product
- TADALAFIL (TADALAFIL)
- Brand
- TADALAFIL
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- Affected units
- 1,113,264
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) P2002450
- Exp. Date 4/30/2023
- P2003222
- Exp. Date 5/31/2023
- P2003223
- P2003224
- P2004636
- Exp. Date 8/31/2023
- P2005035
- P2005038
- P2005040
- P2005039
- P2005041
- P2005606
- Exp. Date 9/30/2023
- P2100340
- P2100009
- Exp. Date 12/31/2023
- P2100010
- P2100044
UPCs (5)
- 0316729372107
- 0316729369107
- 0316729370103
- 316729370103
- 316729370165
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · TADALAFIL
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Tadalafil tablets recalled for manufacturing process deviations
FDA (Drugs) · 2023-04-12
- HighTadalafil tablets recalled for manufacturing quality control deviations
FDA (Drugs) · 2023-03-08
- ModerateTadalafil tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Accord Healthcare, Inc.
See all →- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · manufacturing deviation
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29